The Technical Analyst
Soleno Therapeutics Inc [SLNO]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Soleno Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.03% $37.16
America/New_York / 19 apr 2024 @ 14:05
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 206.24 mill |
| EPS: | -2.36 |
| P/E: | -15.75 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 32.46 mill |
| Avg Daily Volume: | 0.302 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -15.75 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.68x |
| Company: PE -15.75 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$10.26 (-72.38%) $-26.90 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 34.93 - 39.63 ( +/- 6.30%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Yen Kristen | Sell | 1 330 | Common Stock |
| 2024-04-01 | Yen Kristen | Sell | 888 | Common Stock |
| 2024-04-01 | Mackaness James H | Sell | 3 104 | Common Stock |
| 2024-04-01 | Mackaness James H | Sell | 2 071 | Common Stock |
| 2024-04-01 | Hirano Patricia C | Sell | 888 | Common Stock |
| INSIDER POWER |
|---|
| 6.43 |
| Last 99 transactions |
| Buy: 11 271 770 | Sell: 9 891 855 |
Forecast:
15:44 - $37.16
Live Trading Signals (every 1 min)
Forecast
1: 14:14 - $37.29
Forecast 2: 15:04 - $37.07
Forecast 3: 15:44 - $37.16
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $37.16 (0.03% ) |
| Volume | 0.0825 mill |
| Avg. Vol. | 0.302 mill |
| % of Avg. Vol | 27.32 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SLNO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $46.91 | N/A | Active |
|---|
SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Latest Press Releases
2024-03-08 16:05:00 - Press Release
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Redwood city, calif., march 08, 2024 (globe newswire) -- soleno therapeutics, inc. (“soleno”) (nasdaq: slno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by nasdaq stock market rules, the grant of inducement awards to five new employees.
2024-03-06 16:05:00 - Press Release
Soleno Therapeutics Provides Corporate Update And Reports Fourth Quarter And Full-year 2023 Financial Results
Redwood city, calif., march 06, 2024 (globe newswire) -- soleno therapeutics, inc. (soleno) (nasdaq: slno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended december 31, 2023.
2024-02-22 08:00:00 - Press Release
Soleno Therapeutics To Present At The Td Cowen 44th Annual Health Care Conference
Redwood city, calif., feb. 22, 2024 (globe newswire) -- soleno therapeutics, inc. (“soleno”) (nasdaq: slno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that anish bhatnagar, m.d., chief executive officer, will present at the td cowen 44th annual healthcare conference on monday, march 4, 2024, at 1:30 pm eastern time.
2024-02-01 08:00:00 - Press Release
Soleno Therapeutics To Present At Upcoming February Investor Conferences
Redwood city, calif., feb. 01, 2024 (globe newswire) -- soleno therapeutics, inc. (“soleno”) (nasdaq: slno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that anish bhatnagar, m.d., chief executive officer, will present at the following upcoming investor conferences:
2024-01-29 16:05:00 - Press Release
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Redwood city, calif., jan. 29, 2024 (globe newswire) -- soleno therapeutics, inc. (“soleno”) (nasdaq: slno), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by nasdaq stock market rules, the grant of inducement awards to five new employees.
Latest News
2024-02-14 09:51:41 - Zacks Investment Research
Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics, Inc. (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2024-01-26 09:51:03 - Zacks Investment Research
Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going
Soleno Therapeutics, Inc. (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
2024-01-22 22:42:14 - Seeking Alpha
Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
ACADIA Pharmaceuticals and Soleno Therapeutics are both conducting late-stage trials for the treatment of Prader-Willi Syndrome. PWS is a rare disease characterized by various physical and developmental challenges. Acadia is an established commercial stage company, while Soleno is a clinical stage company focused on PWS.
2023-12-27 14:46:00 - Market Watch
The best-performing stock of the year rose nearly 10-fold, while the second-best averted disaster to surge 1,000% in a wild 2023
No, it isn't related to artificial intelligence — although shares of AI-linked chip maker Nvidia Corp. NVDA, +0.16% have surged more than 200% thus far on the year.
2023-12-26 07:15:00 - Finbold
The underdogs of 2023: Small-cap stocks that made it big
In recent years, most reports of assets surging by thousands of percents in relatively short periods come from the crypto market, where various cryptocurrencies – especially smaller altcoins and meme coins – can very quickly make staggering surges.
2023-12-21 18:59:00 - The Motley Fool
Why Soleno Therapeutics Stock Ticked Higher on Thursday
An analyst changed his price target on the clinical-stage biotech. He added 10% to his level, which caught the market's attention.
2023-12-14 15:44:34 - InvestorPlace
Take Profit: 3 Stocks to Sell That Are Up More Than 200% in 2023
The stock market is ending 2023 with outsized gains. Investors are in a cheerful mood, and many speculative stocks to take profits on are soaring right now.
2023-12-14 07:00:00 - InvestorPlace
3 Stock Winners That Are Up 500% or More in 2023
2023 proved to be a wild year, as many investors' top-performing stocks quickly swirled down the drain amid higher interest rates and tightened economic conditions. But, against all odds, the market outlook improved rapidly in early fall before kicking off an early start to the Santa rally.
2023-11-27 13:02:32 - InvestorPlace
Feeling Lucky? 5 ‘Jackpot' Stocks to Buy for 2024.
This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.
2023-11-26 10:47:19 - Seeking Alpha
Soleno Therapeutics: Impressive Data, But Never Forget Amarin
Soleno Therapeutics has seen a surge in stock value after positive data from Phase III trials of its Diazoxide Choline Extended-Release tablet for Prader-Willi Syndrome. The data showed improvements in body composition and hyperphagia-related behaviors in patients treated with the tablet. Soleno Therapeutics faces potential challenges in protecting its intellectual property for the formulation of the drug.